GlaxoSmithKline to Use Inpharmatica s ADME Technology | GenomeWeb

NEW YORK, March 22 (GenomeWeb News) - Inpharmatica has made its ADME (absorption, distribution, metabolism, and excretion) technology available to GlaxoSmithKline, the company said today.

 

Under the agreement, Inpharmatica, based in London, will apply its ADME technology to a number of GSK's drug discovery programs in the UK and in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.